

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Strategic Thinking in Test Selection for Mass SARS-CoV-2 Testing

Sejal Morjaria¹, Rosa Nouvini², S. Joseph Sirintrapun³

Author Affiliations:

¹Infectious Disease, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY

²Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY

³Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, NY

Corresponding Author:

S. Joseph Sirintrapun, MD

Email: sirintrs@mskcc.org

© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.

22

Introduction

23 Effective mass SARS-CoV-2 testing is critical to mitigating COVID-19 outbreaks and alleviating the
24 economic impact of COVID-19 lockdowns. Although vaccination will stymie severe infection and
25 potentially mitigate spread, the possibility of asymptomatic transmission, logistical issues with
26 vaccinating entire communities in a timely fashion and the questionable duration of immunity
27 jeopardize infection control. The threat of new variants escaping vaccine induced immunity and leading
28 to outbreaks also remains. For this reason, a robust testing and vaccination strategy must be
29 implemented alongside each other. Likewise, robust testing to control transmission helps maintain
30 COVID-19 elimination status once achieved either through post-infection surges or vaccination efforts. It
31 is important to not only test and quarantine individuals who display symptoms of COVID-19 but to also
32 identify individuals who are asymptomatic and pre-symptomatic. These individuals are significant
33 contributors to community SARS-CoV-2 transmission (1) and their identification can help curb outbreaks.
34 This is especially important for vulnerable communities that contain individuals of lower socioeconomic
35 status, who are often essential workers who rely on public transportation. Such communities contain a
36 higher proportion of ethnic minorities and often have higher rates of COVID-19 (2).

37 Given the variability of COVID-19 susceptibility and prevalence amongst communities, a
38 comprehensive SARS-CoV-2 testing strategy that combines economic, logistic, and public health
39 considerations must be adopted. As a starting point, we show a thought experiment with four
40 commonly encountered scenarios on how strategic thinking in SARS-CoV-2 testing can tailor healthcare
41 policies based on community factors.

42

Absence of Strategic Thinking to Testing

43 At the onset of the pandemic, no national testing strategy existed, leaving states and local jurisdictions
44 to develop their own. The testing landscape that emerged varied widely, with more wealthy states and
45 robust medical sectors devising comprehensive plans, while other states lagged behind. Furthermore,

46 some testing gaps in local communities required a federal strategy to solidify production and supply
47 chain logistics (3) which has been lagging throughout the pandemic. Even in New York, one of the richest
48 states, communities of lower socioeconomic status and minority groups, where rates of COVID-19
49 positivity and deaths were greatest, had less access to testing (4).

50 **Two Imperfect Approaches to Testing**

51 Public health experts, such as Mina et al. have advocated for a nationwide rapid testing program using
52 paper-based antigen tests. Such point-of-care tests (POCTs) offer accessibility and operational simplicity
53 for mass SARS-CoV-2 testing. However, POCTs are less sensitive and specific than PCR which can lead to
54 further viral spread for an FN (5). POCTs advocates show that when factoring viral load kinetic patterns,
55 high testing frequency with rapid turnaround times (TATs) and affordability to dispense on a massive
56 scale, POCTs can overcome its lower sensitivity versus PCR testing. They further conclude that POCTs
57 are most effectively used in communities where the transmissibility window is highest (6).

58 In contrast, the Great Barrington Declaration argues for communities to “perform frequent
59 polymerase chain reaction (PCR) testing” (7). Though PCR testing is the most accurate, PCR testing lacks
60 the accessibility and operational simplicity of POCTs. It also is susceptible to false-positive (FP) results
61 given its high sensitivity. FPs also pose individual risks and can undermine confidence in clinical and
62 public health efforts. As an example, FP results can delay asymptomatic patients from undergoing
63 potentially curative cancer surgery and chemotherapy. PCR also depends on strained supply chains and
64 technical expertise for processing. Such dependencies lead to slow turnaround times (TATs) for results
65 and higher testing expenses. Slow TATs can render PCR results obsolete if contagious individuals
66 continue exposing others while awaiting results. Moreover, mass PCR testing requires costly laboratory
67 equipment, expertise and testing supplies that are scarce in under-resourced communities.

68 In this paper, we do not incorporate a specimen pooling strategy for simplicity in our quest to
69 illustrate strategic thinking in the COVID-19 domain. Although specimen pooling has advantages in

70 conserving lab reagents and resources, reducing TATs, and lowering costs (8), it is riddled with flaws.
71 Specimen pooling is prone to FN results due to sample dilution, making it applicable only in low COVID-
72 19 prevalence communities. Moreover, this testing strategy is mostly unregulated, requiring laboratory
73 expertise, not often accessible in under-resourced communities. Lastly, guidelines are absent on the
74 optimal number of individual samples pooled before FN results arise (8).

75 **Framework for Strategic Thinking in SARS-CoV-2 Test Selection**

76 Our strategic framework for SARS-CoV-2 test selection accounts for three factors: 1) whether a
77 community is a “cold spot” (low COVID-19 prevalence) or “hot spot” (high COVID-19 prevalence), 2)
78 whether a community has a limited testing capacity, and 3) whether the specific scenario warrants the
79 aforementioned desirable testing features (accessibility, fast TATs, high test accuracy). By evaluating
80 these factors and making a public health risk assessment, we provide an optimal testing strategy with
81 testing logistics and performance along with policy recommendations.

82 Important measurements of test performance include sensitivity, specificity, positive predictive
83 value (PPV) and negative predictive value (NPV). PPV and NPV are meaningful in a clinical setting, but
84 these values depend on the COVID-19 prevalence. Take a cold spot community, for example, which can
85 either be one not affected by COVID-19, post-surge, or with a high level of population immunity via
86 vaccination or natural infection. The NPV for such a community is higher given the low amount of
87 circulating virus. In hot spot communities, on the other hand, PPV is higher given the higher amount of
88 circulating virus (9).

89 Of import, people of color and low socioeconomic status often reside in hot spot communities
90 with limited testing capacities (4). There is an urgency to create better testing strategies for them as
91 such populations have more COVID-19 cases and suffer more morbidity and mortality. According to the
92 CDC, when compared to non-Hispanic White persons, Black, Hispanic and American Indian/Alaska Native
93 persons are 2.8, 2.8 and 2.6 times more likely to die from COVID-19, respectively (10). Part of these

94 disproportionate effects arises from existing healthcare and structural disparities that have led to a
95 higher prevalence of severe COVID-19 risk comorbidities such as respiratory illnesses and hypertension
96 (C11). Furthermore, structural disparities such as living in multigenerational homes and employment as
97 essential workers makes social distancing and quarantine/isolation much more difficult thereby
98 increasing the risk of contracting COVID-19. Despite these known risks, these communities often have
99 less access to testing than their wealthier neighboring communities as was seen in New York City during
100 the surge (4). This argues for increasing the availability of POCTs given their higher accuracy in such
101 higher prevalence settings as well as their lower cost and resource utilization.

102 **Thought Experiment**

103 Taking all of this into consideration, we introduce thought experiments for four frequently encountered
104 community scenarios (**Figure 1**).

105 Scenario 1 applies to the asymptomatic screening of non-vulnerable individuals in a cold spot
106 community for sporadic interactions. Sporadic interactions include testing all individuals dining at
107 restaurants and shopping at malls, where the penalty for high FPs and FNs is more tolerable for less
108 vulnerable younger, healthier populations prone to doing such activities and less likely to have severe
109 COVID-19 outcomes. POCTs work best because of the desirable features of easy accessibility and fast
110 TATs.

111 Scenario 2 includes individuals in a cold spot community with continual exposure to vulnerable
112 patients like those in nursing homes and many segments of populations of color. In these healthcare
113 settings, testing is critical to mitigating the impact of COVID-19. Here, accurate tests with high PPV and
114 NPV are paramount, which means a testing strategy that must incorporate PCR testing. Given the known
115 pitfalls of PCR testing (poor accessibility and slow TATs), logistics and policy responses to increase
116 testing supplies and facilities for these individuals are necessary. Alternatively, to improve the detection

117 of COVID-19 disease, new testing guidelines can consider the combined integrated use of POCTs and
118 PCR testing for SARS-CoV-2.

119 Scenario 3 includes individuals with a COVID-19 symptom complex (i.e., loss of smell plus taste)
120 (12) in a cold spot community with limited testing capacity. In such communities, POCTs provide the
121 only available and viable means of testing (9). Though the NPV is better given the lower prevalence in
122 those communities, a negative test is not a trusted license to interact with vulnerable populations and
123 engage in transmissible behaviors. Because of the non-overlap between the windows of viral
124 transmissibility and timing of tests in obtaining a positive result, the use of serial POCTs targeted to
125 various SARS-CoV-2 antigens would increase the test's sensitivity and achieve a sufficient trust level for a
126 series of negative results (13). The optimal serial testing regimen, leveraging different antigens and
127 specific testing time intervals, remain under investigation.

128 The most conservative policy is restrictions for all individuals with the COVID-19 symptom
129 complex, regardless of the test result. This policy, however, potentially disengages a significant subset of
130 the community that may have essential duties. It also potentially results in non-compliance to COVID-19
131 restrictions if the FP rate is too high. The optimal approach is the judicious yet integrated approach in
132 using PCR, when available, to confirm negatives when the penalty of inaccuracy is high, such as those
133 who interact with vulnerable populations. Unfortunately, there is no available research on the optimal
134 integrated use of POCTs with limited PCR to help these communities.

135 Scenario 4 are individuals in hot spot communities with limited testing capacity who develop a
136 new cough onset. New cough onset alone is arguably predictive for SARS-CoV-2 positivity in a
137 community with a high COVID-19 prevalence. However, the current state where tests get performed
138 infrequently cannot stop transmission chains. As stated above, though not as accurate as PCR tests,
139 POCTs tests are very cheap to produce and can be performed by individuals much more frequently. And
140 such POCTs are nonetheless effective at detecting virus when individuals are most infectious (14).

141 Fast TATs with rapid results from POCTs are critical to interrupting SARS-CoV-2 transmission,
142 particularly in hot spot communities with outbreak settings or clusters with high transmission levels.
143 Positive results from POCTs combined with new cough onset further substantiate SARS-CoV-2 positivity,
144 justifying quarantine. If positive individuals, particularly those with new-onset cough, stay home and
145 quarantine measures get enforced, the widespread effect breaks transmission chains across the country,
146 similar to vaccine deployment. Therefore, for individuals with a new onset of cough, negative results
147 from POCTs are more suspect than in a cold spot community. Because of the ramifications of testing
148 inaccuracy with POCTs, creating a better policy to prioritize mass PCR testing for such communities
149 should be attempted.

150 Overall, our testing strategy will increase the accessibility and therefore the frequency of
151 testing. This in turn will allow for transmission control, infection rate monitoring and mitigating the
152 impact of COVID-19 in healthcare and social care settings **(Table 1)**.

153

154 **Conclusion**

155 Mass SARS-CoV-2 testing and other proven strategies (social distancing, mask-wearing, etc.)
156 help mitigate COVID-19 and its community impacts. We address the most significant gap in the COVID-
157 19 public policy conversation: a one-size-fits-all mass testing edict. By leveraging testing resources
158 strategically, our framework applies risk assessments for frequently encountered community scenarios.

159 Our thought experiments show logical reasoning, based on community variables, in selecting,
160 prioritizing, and allocating testing resources to communities affected by the COVID-19 pandemic. We
161 intend for our thought experiments to stimulate consensus among expert groups, presumably consisting
162 of physicians, health policymakers, epidemiologists, economists, and politicians. Such groups are more
163 apt to build testing strategies with logistics and policy for more complicated community scenarios, like

164 “back to school/college” and “return to work” situations, that optimize individual health, public health,
165 and economic interests.

166

167 **Author Contributions:** *All authors confirmed they have contributed to the intellectual content of this*
168 *paper and have met the following 4 requirements: (a) significant contributions to the conception and*
169 *design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for*
170 *intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for*
171 *all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of*
172 *the article are appropriately investigated and resolved.*

173

174 S.J. Sirintrapun, administrative support, provision of study material or patients.

175

176 **Authors' Disclosures or Potential Conflicts of Interest:** *No authors declared any potential conflicts of*
177 *interest.*

178

179

180

References

- 181 1. Centers for Disease Control. Guidance for expanded screening testing to reduce silent
182 spread of sars-cov-2. https://www.cdc.gov/coronavirus/2019-ncov/php/testing/expanded-screening-testing.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fphp%2Fopen-america%2Fexpanded-screening-testing.html. (Accessed February
186 2021)
- 187 2. Karmakar M, Lantz PM, Tipirneni R. Association of social and demographic factors with
188 covid-19 incidence and death rates in the US. *JAMA Netw Open* 2021;4:e2036462.
- 189 3. The Washington Post. In the absence of a national testing strategy, states go their own way.
190 <https://www.washingtonpost.com/health/2020/04/07/testing-coronavirus-trump/>
191 (Accessed February 2021)
- 192 4. Lieberman-Cribbin W, Tuminello S, Flores RM, Taioli E. Disparities in covid-19 testing and
193 positivity in new york city. *Am J Prev Med* 2020;59:326-32.
- 194 5. Brooks ZC, Das S. Covid-19 testing. *Am J Clin Pathol* 2020;154:575-84.
- 195 6. Mina MJ, Parker R, Larremore DB. Rethinking covid-19 test sensitivity - a strategy for
196 containment. [Editorial]. *N Engl J Med* 2020;383:e120.

197 7. Great Barrington Declaration. The great barrington
198 declaration. <https://gbdeclaration.org/> (Accessed December 2020)
199 8. Centers for Disease Control. Interim guidance for use of pooling procedures in sars-cov-2
200 diagnostic, screening, and surveillance testing. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html)
201 [ncov/lab/pooling-procedures.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html) (Accessed February 2021)
202 9. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic
203 covid-19 tests. *Nat Rev Microbiol* 2021;19:171–83.
204 10. Centers for Disease Control. Covid-19 hospitalization and death by
205 race/ethnicity. [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html)
206 [discovery/hospitalization-death-by-race-ethnicity.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html). (Accessed January 2021)
207 11. Alcendor DJ. Racial disparities-associated covid-19 mortality among minority populations in the
208 us. *J Clin Med* 2020;9:2442.
209 12. Centers for Disease Control. Symptoms of coronavirus. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html)
210 [ncov/symptoms-testing/symptoms.html](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html) (Accessed February 2021)
211 13. He Xi, Lau EHY, Wu P, Deng X, Wang, J, Hao X, et. al. Temporal dynamics in viral shedding and
212 transmissibility of COVID-19. *Nat Med* 2020;26:672–75
213 14. *The Harvard Gazette*. Cheap, frequent covid tests could be ‘akin to vaccine,’ professor says.
214 [https://news.harvard.edu/gazette/story/2020/08/cheap-daily-covid-tests-could-be-akin-to-](https://news.harvard.edu/gazette/story/2020/08/cheap-daily-covid-tests-could-be-akin-to-vaccine/)
215 [vaccine/](https://news.harvard.edu/gazette/story/2020/08/cheap-daily-covid-tests-could-be-akin-to-vaccine/). (Accessed February 2021)
216
217
218
219
220
221
222
223
224
225
226
227
228
229

230 **Table 1:** How a Mass Testing Strategy Will Help Control Transmission, Monitor Rates and Mitigate the
 231 Impact of COVID-19 in Healthcare and Social Settings
 232

	To Control Transmission	To Monitor Rates	To Mitigate the Impact of COVID-19 in Healthcare and Social Settings
Solution	Affordable POCTs provide the scaled accessibility and high testing frequencies for any resourced community	POCTs provide the affordability for scaled accessibility and high testing frequencies for any resourced community	POCTs provide the scaled accessibility and high testing frequencies that healthcare and social care setting need, covering the subsequent time periods after diagnostic PCR testing
	POCTs can be leveraged at scale to detect clusters and outbreaks in any specific setting, which in turn controls transmission, while continually monitoring rates and mitigating impacts of COVID-19 in those specific settings		
Reasoning	A significant proportion of transmission occurs through asymptomatic spread, and testing the asymptomatic population requires scaled accessibility and high testing frequencies to catch the initiation of clusters and outbreaks in specific settings	Monitoring requires scaled accessibility and high testing frequencies	Healthcare and social care settings may not have the ability for sustained continuous diagnostic PCR testing, and POCTs fill that gap where diagnostic PCR testing is not continually available
	With vaccinations underway, questions still remain of vaccination durations and breakthrough infections, POCTs can be an integral scalable component to maintaining COVID-19 elimination status once achieved		

233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244

245 **Figure Captions:**

246

247 **Figure 1: SARS-COV-2 Testing Strategy for Four Commonly Encountered Community Scenarios**

248

	Desired Features of Testing Strategy			Testing Regimen	Risk Assessment	Logistics and Policy
"Cold spot" Community						
Scenario 1: Asymptomatic individual screening and daily sporadic interactions between non-vulnerable individuals	Easy Accessibility	Fast TAT	NPV is a priority	POC testing (i.e. PATs)	Though not perfect, NPV is better and possibly acceptable, given the lower community prevalence. Likewise, the penalty of FN is lower, given the scenario is screening and non-vulnerable individuals. Consider that PPV is lower.	Restrictions and isolation for "spreader" individuals testing positive, particularly those interacting with vulnerable subpopulations. Follow-up of positive tests with confirmatory PCR.
Scenario 2: Individuals with continual interactions with vulnerable subpopulations	Easy Accessibility	Fast TAT	PPV and NPV is a priority	PCR	The high penalty for FP and FN results are best addressed by performing PCR testing regimens.	Increase PCR testing supplies and improve logistics for deployment to enhance accessibility and TAT.
"Cold spot" Community with limited testing capacity						
Scenario 3: Individuals developing a new onset of predictive COVID-19 associated symptoms	Easy Accessibility	Fast TAT	PPV and NPV is a priority	Start with POC testing (i.e. PATs). Develop serial POC testing regimens to strengthen trust in the POC results. Consider judicious use of follow-up PCR testing (when available).	NPV more trustworthy, particularly when a developed serial POC testing regimen is negative. PPV is lower, though developing a serial POC testing regimen may enhance the sensitivity.	Weighing the penalty of a FN, consider confirmatory PCR (if available) where the penalty is high. Or without PCR, blanket restrictions for all with symptoms where penalty is high.
"Hot spot" high RO, high COVID-19 prevalence community with limited testing capacity						
Scenario 4: Individuals developing a new onset cough	Easy Accessibility	Fast TAT	PPV and NPV is a priority	Start with POC testing (i.e. PATs). Develop serial POC testing regimens to strengthen trust in the POC results. Consider judicious use of follow-up PCR testing (when available).	PPV more trustworthy, negatives are more suspect.	Weighing the penalty of a FN, consider confirmatory PCR (if available) where the penalty is high. Or without PCR, blanket restrictions for all with symptoms where penalty is high. The latter may not be practical given that such communities in reality, regularly interact with vulnerable subpopulations. Therefore, efforts should be made to increase access to more accurate confirmatory tests like PCR.

What the testing regimen delivers for desirable features of the testing strategy.

What is not associated with the testing regimen and must be worked upon to meet the desirable features of the testing strategy.

- NPV = Negative predictive value
- PPV = Positive predictive value
- POC = Point of care
- FN = False negative
- FP = False positive
- PATs = Paper-based antigen tests
- TAT = Turn-around time
- RO = Level of contagiousness

249

250

251